OVERVIEW
Myelofibrosis (MF) is a rare disease that has a significant impact on patient’s quality of life. While many remain symptom-free for years, ultimately symptoms impose a major burden. While Janus kinase (JAK) inhibitors play an important role in treating MF, a variety of novel targeted therapies are in clinical development that have the potential to prevent/delay resistance to ruxolitinib, alter the course of the disease, and improve patient outcomes. This interactive symposium will begin with an overview of the challenges associated with the current management of MF from a physician’s perspective; followed by an interview with a patient with MF to highlight the issues patients face. We then continue with a deeper dive into the biological path of MF, how to target the stem cell and microenvironment in MF, the path of epigenetic dysregulation fueling the development of epigenetic therapies, as well as other emerging therapies in myeloproliferative neoplasms. The session will conclude with a group discussion reviewing how these new developments may positively impact the evolving journey of patients living with MF.
GOAL STATEMENT
The goal of this activity is for learners to be better able to understand the pathogenesis of myelofibrosis (MF), the challenges associated with current therapies from both physician and patient perspectives, and the novel epigenetic therapies in clinical development aiming to have a positive impact on MF by advancing outcomes and changing the course of the disease.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST] [ITEM]Challenges faced by patients in their journey with MF [ITEM]Pathogenesis of MF [ITEM]Biological rationale for developing novel therapies for treating MF [ITEM]Available clinical evidence with novel therapies for MF and other MPNs[/LIST] Demonstrate greater confidence in their ability to [LIST] [ITEM]Describe the role of novel epigenetic therapies in advancing outcomes for patients with MF[/LIST]
ACCREDITATION STATEMENT
[JALOGO][MEDSCAPE] In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.5 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Marriott Marquis San Diego Marina
Room: Grand Ballroom 8-9
333 W Harbor Drive
San Diego, California, 92101
United States
Friday Satellite Symposium on Hematology/Oncology preceding the 65th ASH Annual Meeting and Exposition.
Supported by an independent educational grant from [bold]Morphosys.[/bold]